Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the registration statement on Form S-4 (the “Registration Statement”), related to the previously announced proposed business combination (the “Business Combination”) between Denali Capital Acquisition Corp. ("Denali") (OTCB: DNQAF), a special purpose acquisition company, and Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex, has been declared effective by the U.S. Securities and Exchange Commission (the "SEC").

Read more at globenewswire.com